Why does ticagrelor induce dyspnea?

Summary

In studies that compared the reversible P2Y12 inhibitor ticagrelor with the irreversible inhibitor clopidogrel, dyspnea was observed more frequently among ticagrelor-treated patients than among clopidogreltreated patients. Because dyspnea was not associated with acidosis, pulmonary or cardiac dysfunction, alterations in the mechanisms and pathways of the sensation of dyspnea may be involved in its pathogenesis. It has been hypothesised that the sensation of dyspnea in ticagrelor-treated patients is triggered by adenosine, because ticagrelor inhibits its clearance, thereby increasing its concentration in the circulation. However, dipyridamole, a much stronger inhibitor of adenosine clearance than ticagrelor, usually does not cause dyspnea. We hypothesise that inhibition of P2Y12 on sensory neurons increases the sensation of dyspnea, particularly when reversible inhibitors are used. We base our hypothesis on the following considerations: 1) cangrelor and elinogrel, which, like ticagrelor, are reversible P2Y12 inhibitors, also increase the incidence of dyspnea;2) it is biologically plausible that inhibition of P2Y12 on sensory neurons increases the sensation of dyspnea;3) inhibition of P2Y12 on platelets (which do not have a nucleus) by clopidogrel is permanent, despite the once daily administration and the short plasma half-life of the inhibitor;4) in contrast, inhibition of P2Y12 on neurons by clopidogrel may be temporary and transient, because neurons have a nucleus and can therefore rapidly replace the inhibited receptors with newly synthetised ones;5) inhibition of P2Y12 on neurons by reversible inhibitors is permanent, because the plasma drug concentration is maintained high by repeated dosing, in order to ensure permanent inhibition of platelet P2Y₁₂.

Keywords

ADP receptors - arterial thrombosis - nervous system

• References

• 1 Cattaneo M. The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 2011; 117: 2102-2112.
• 2 Cattaneo M. New P2Y12 Inhibitors. Circulation 2010; 121: 171-179.
• 3 Wallentin L, Becker RC, Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
• 4 Husted S, Emanuelsson H, Heptinstall S. et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038-1047.
• 5 Cannon CP, Husted S, Harrington RA. et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50: 1844-1851.
• 6 Gurbel PA, Bliden KP, Butler K. et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120: 2577-2585.
• 7 Storey RF, Bliden KP, Patil SB. et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol 2010; 56: 185-193.
• 8 Gurbel PA, Bliden KP, Butler K. et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121: 1188-1199.
• 9 Storey RF, Becker RC, Harrington RA. et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J 2011; 32: 2945-2953.
• 10 Harrington RA, Stone GW, McNulty S. et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361: 2318-2329.
• 11 Welsh RC, Rao SV, Zeymer U. et al. A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention: The INNOVATE-PCI Trial. Circ Cardiovasc Interv 2012; 5: 336-346.
• 12 Bhatt DL, Lincoff AM, Gibson CM. et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330-2341.
• 13 Angiolillo DJ, Firstenberg MS, Price MJ. et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. J Am Med Assoc 2012; 307: 265-274.
• 14 Serebruany V, Pokov I, Kuliczkowski W. et al. Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting. Thromb Haemost 2008; 100: 314-318.
• 15 Storey RF, Becker RC, Harrington RA. et al. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patients Outcomes (PLATO) pulmonary function substudy). Am J Cardiol 2011; 108: 1542-1546.
• 16 Burki NK, Lee L- Y. Mechanisms of dyspnea. Chest 2010; 138: 1196-1201.
• 17 Van Giezen JJ, Sidaway J, Glaves P. et al. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hypermeia responses in a canine model. J Cardiovasc Pharmacol Ther 2012; 17: 164-172.
• 18 Ranhosky A, Kempthorne-Rawson J. The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Intravenous Dipyridamole Thallium Imaging Study Group. Circulation 1990; 81: 1205-1209.
• 19 Wiviott SD, Braunwald E, McCabe CH. et al. TRITON-TIMI 38 Investigators.Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
• 20 Food and Drug Administration (FDA). Effient (prasugrel) tablets label. Available at. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022307s003lbl.pdf page 6. Accessed: June 18, 2012.
• 21 Unterberger U, Moskvina E, Scholze T. et al. Inhibition of adenylyl cyclase by neuronal P2Y receptors. Br J Pharmacol 2002; 135: 673-684.
• 22 Malin SA, Molliver DC. Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior. Mol Pain 2010; 6: 21-25.
• 23 Kubista H, Lechner SG, Wolf AM. et al. Attenuation of the P2Y receptor-mediated control of neuronal Ca2+ channels in PC12 cells by antithrombotic drugs. Br J Pharmacol 2003; 138: 343-350.
• 24 Zhang G, Lee LY. Prostaglandin E2 enhances the sensitizing effect of hyperthermia on pulmonary C-fibers in rats. Respir Physiol Neurobiol 2007; 156: 241-249.
• 25 Taguchi O, Kikuchi Y, Hida W. et al. Prostaglandin E2 inhalation increases the sensation of dyspnea during exercise. Am Rev Respir Dis 1992; 145: 1346-1349.
• 26 Cattaneo M, Lecchi A. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost 2007; 5: 577-582.
• 27 Husted SE, Storey RF, Bliden K. et al. Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease: Results from the ONSET-OFFSET and RESPOND Studies. Clin Pharmacokinet 2012; 51: 397-409.
• 28 Storey RF. Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thromb Haemost 2011; 105 (Suppl. 01) 75-81.
• 29 Angiolillo DJ, Welsh RC, Trenk D. et al. Pharmacokinetic and Pharmacodynamic Effects of Elinogrel: Results of the Platelet Function Substudy From the Intravenous and Oral Administration of Elinogrel to Evaluate Tolerability and Efficacy in Nonurgent Percutaneous Coronary Intervention Patients (INNOVATE-PCI) Trial. Circ Cardiovasc Interv 2012; 5: 347-356.
• 30 Payne CD, Li YG, Small DS. et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007; 50: 555-562.
• 31 Dieterich DC, Hodas JJ, Gouzer G. et al. In situ visualization and dynamics of newly synthesized proteins in rat hippocampal neurons. Nat Neurosci 2010; 13: 897-905.
• 32 Manning HL, Schwartzstein RM. Pathophysiology of dyspnea. N Engl J Med 1995; 333: 1547-1553.
• 33 Serebruany VL, Stebbing J, Atar D. Dyspnoea after antiplatelet agents: the AZD6140 controversy. Int J Clin Pract 2007; 61: 529-533.
• 34 Craig AD. Interoception: the sense of the physiological condition of the body. Curr Opin Neurobiol 2003; 13: 500-5.
• 35 Jakubowski JA, Winters KJ, Naganuma H. et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007; 25: 357-374.